Second-Line Eltrombopag in Adults With Primary Immune Thrombocytopenia to Achieve Sustained Remission Off-Treatment
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
British Journal of Haematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Eltrombopag Second-Line Therapy in Adult Patients With Primary Immune Thrombocytopenia in an Attempt to Achieve Sustained Remission Off-Treatment: Results of a Phase II, Multicentre, Prospective Study
Br. J. Haematol 2021 Feb 22;[EPub Ahead of Print], E Lucchini, F Palandri, S Volpetti, N Vianelli, G Auteri, E Rossi, A Patriarca, G Carli, W Barcellini, M Celli, U Consoli, F Valeri, C Santoro, E Crea, M Vignetti, F Paoloni, CL Gigliotti, E Boggio, U Dianzani, I Giardini, M Carpenedo, F Rodeghiero, R Fanin, F Zaja, for Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA)From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.